OLIVE ECKSTEIN to Treatment Outcome
This is a "connection" page, showing publications OLIVE ECKSTEIN has written about Treatment Outcome.
Connection Strength
0.115
-
Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study. Arthritis Rheumatol. 2025 Feb; 77(2):226-238.
Score: 0.018
-
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab. Blood Adv. 2024 05 14; 8(9):2248-2258.
Score: 0.018
-
Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1888-1893.
Score: 0.018
-
Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1882-1887.
Score: 0.018
-
Persistent fever in a pediatric renal transplant patient: Questions. Pediatr Nephrol. 2019 05; 34(5):823-824.
Score: 0.012
-
Persistent fever in a pediatric renal transplant patient: Answers. Pediatr Nephrol. 2019 05; 34(5):825-828.
Score: 0.012
-
Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018 11; 142(5):1665-1669.
Score: 0.012
-
Non-invasive cardiac output and oxygen delivery measurement in an infant with critical anemia. J Clin Monit Comput. 2011 Apr; 25(2):113-9.
Score: 0.007